Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 60 years or older
- People diagnosed with prostate cancer that is contained within the prostate (has not spread) and is classified as low or intermediate risk (stages T1 or T2)
- People whose prostate cancer has a Gleason score of 6 or 7 (a measure of how the cancer cells look under a microscope)
- People whose PSA level (a protein measured in the blood related to prostate health) is below 15 ng/mL
- People who show no signs that the cancer has spread to other parts of the body
- People for whom radiation therapy has been recommended as a treatment for their prostate cancer
- People who are covered by the French social security system
- French-speaking people
- People who have been fully informed about the trial and have signed a written consent form
Who may not be able to join:
- People who are unable to read, write, or understand French
- People who are considered vulnerable patients under a specific French public health law (confirm with trial site)
- People who are under guardianship, curatorship, or a form of legal protection under French law
- People who are unable to personally give their own informed consent under French public health law
- People who are already taking part in another interventional research study that could affect the results of this trial
- People who have previously had surgery on the prostate or digestive system that could affect the trial's results
- People who decline to sign the written informed consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Youssef Slama, Clinique Sainte Clotilde
Phone: 0692341365
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients requiring dosimetric recalculation due to anatomical variations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.